# OnCo record cou-aa-301 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/cou-aa-301/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "cou-aa-301", "NCT00638690" ;
  schema:name "COU-AA-301"@en ;
  schema:alternateName "COU-AA-301"@en, "abiraterone after docetaxel"@en ;
  schema:description "Proved that prostate cancer which has stopped responding to standard hormone therapy is still driven by androgens, by blocking the enzyme that makes them and adding about four months of life."@en ;
  schema:url <https://onco.cc/trials/cou-aa-301/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00638690>, <https://doi.org/10.1056/NEJMoa1014618>, <https://www.nice.org.uk/guidance/ta259> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/androgen-deprivation/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/abiraterone/>, <https://onco.cc/drugs/prednisone/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:terms <https://onco.cc/terms/arpi/>, <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/psa50/> ;
  onco:trials <https://onco.cc/trials/cou-aa-302/>, <https://onco.cc/trials/affirm/>, <https://onco.cc/trials/tax-327/> .